Sign In
Buy KNBIF
$0.0250
+0 (+0%)
At Close: Jun 22, 2026
Kane Biotech Announces Grant of Stock Options
05:05pm, Friday, 29'th May 2026
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 29, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane”
Kane Biotech Announces First Quarter 2026 Financial Results
05:05pm, Thursday, 28'th May 2026
WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results.
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
07:25am, Tuesday, 26'th May 2026
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 26, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane”
Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress
07:25am, Wednesday, 13'th May 2026
Case study presented highlighted clinical experience with revyve® in complex wound care Case study presented highlighted clinical experience with revyve® in complex wound care
Kane Biotech Announces New Private Placement Offering
07:25am, Thursday, 07'th May 2026
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane”
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
06:00pm, Thursday, 23'rd Apr 2026
WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financi
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
07:25am, Tuesday, 17'th Mar 2026
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article au
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
07:25am, Tuesday, 10'th Mar 2026
WINNIPEG, Manitoba, March 10, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (Kane or the Company), transforming wound care with three FDA 510(k) cleared and two Health Canada approved formats, is pleased
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
07:25am, Friday, 20'th Feb 2026
WINNIPEG, Manitoba, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE) (“Kane Biotech” or “Kane”) announces the publication of an article on its revyve® Antimicrobial wound gel
Kane Biotech Expands Commercial Activities in the United States
07:25am, Thursday, 19'th Feb 2026
WINNIPEG, Manitoba, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has signed non-exclusive distribution/sales agreem
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
07:25am, Tuesday, 17'th Feb 2026
Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio Company expands ISO 13485/MDSAP Certification to support growing wound care portfolio
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
07:25am, Thursday, 18'th Dec 2025
Not for distribution to U.S. news wire services or dissemination in the United States Not for distribution to U.S. news wire services or dissemination in the United States
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
07:25am, Wednesday, 17'th Dec 2025
WINNIPEG, Manitoba, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) announces that it presented new clinical and scientific data a
Kane Biotech Announces Third Quarter 2025 Financial Results
07:25am, Friday, 28'th Nov 2025
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results.
Kane Biotech Announces New Private Placement Offering
07:25am, Thursday, 27'th Nov 2025
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane�
